Site‐specific N‐glycosylation analysis of human factor XI: Identification of a noncanonical NXC glycosite

Human factor XI (hFXI) is a 160‐kDa disulphide‐linked homodimer zymogen involved in the coagulation cascade. Its deficiency results in bleeding diathesis referred to as hemophilia C. hFXI bears five N‐glycosylation consensus sites per monomer, N₇₂, N₁₀₈, N₃₃₅ on the heavy chain and N₄₃₂, N₄₇₃ on the light chain. This study reports the first in‐depth glycosylation analysis of hFXI based on advanced MS approaches. Hydrophilic interaction LC and MS characterization and quantification of the N‐glycans showed that the two major forms are complex biantennary mono‐α2,6‐sialylated (A₂S₁, 20%) and bis‐α2,6‐sialylated structures (A₂S₂, 66%). Minor triantennary structures (A₃S₃F, ～1.5%; A₃S₃, ～2%) were also identified. MS analyses of intact hFXI revealed full occupation of two of the three heavy‐chain glycosites and almost full‐site occupancy of the light chain. Analysis of hFXI glycopeptides by LC‐MS/MS enabled site‐specific glycan profiling and occupancy. It was evidenced that N₃₃₅ was not glycosylated and that N₇₂ and N₁₀₈ were fully occupied, whereas N₄₃₂ and N₄₇₃ were occupied at about 92 and 95%, respectively. We also identified a new glycosite of the noncanonical format NXC at N₁₄₅, occupied at around 5%. These data provide valuable structural information useful to understand the potential roles of N‐glycosylation on hFXI function and could serve as a structural reference.